Statements (20)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:biotechnology
|
| gptkbp:acquiredBy |
Harmony Biosciences
|
| gptkbp:acquisitionYear |
2023
|
| gptkbp:CEO |
Armando Anido
|
| gptkbp:developedBy |
Zygel
|
| gptkbp:focusesOn |
transdermal cannabinoid therapies
|
| gptkbp:foundedYear |
2007
|
| gptkbp:headquartersLocation |
Devon, Pennsylvania, United States
|
| https://www.w3.org/2000/01/rdf-schema#label |
Zynerba Pharmaceuticals
|
| gptkbp:industry |
pharmaceuticals
|
| gptkbp:publiclyTraded |
Yes
|
| gptkbp:stockExchange |
gptkb:NASDAQ
|
| gptkbp:stockSymbol |
ZYNE
|
| gptkbp:website |
https://www.zynerba.com/
|
| gptkbp:ZygelIndication |
gptkb:Autism_spectrum_disorder
gptkb:Fragile_X_syndrome Developmental and epileptic encephalopathies |
| gptkbp:bfsParent |
gptkb:Aisling_Capital
gptkb:CARIN_Alliance |
| gptkbp:bfsLayer |
8
|